Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
Eli Lilly and Company (2)
65 Articles Available
2
3
Can't find what you're looking for? Try our
advanced search
.
Positive Results
Lilly Presents Positive Results for Taltz® vs. Humira®in Patients with Active Psoriatic Arthritis
PR-M06-19-NI-023
Pain Treatment
Eli Lilly Acquires Rights to Non-Opioid Pain Treatment
PAO-M05-19-NI-038
Biosimilar
Successful Results Reported for Another Rituximab Biosimilar
PAO-M05-19-NI-020
Legal
U.S. Court of Appeals Rules in Favor of Lilly in Alimta Vitamin Regimen Patent Lawsuit
PR-M04-19-NI-089
Licensing Agreement
Transcenta Holding Announces Licensing Agreement with Lilly
PR-M04-19-NI-016
Collaboration
Lilly and ImmuNext Announce Licensing and Research Collaboration
PR-M03-19-NI-086
Finance
Lilly Announces Final Results of Elanco Exchange Offer
PR-M03-19-NI-046
Enpoint
Lilly's CYRAMZA® Phase 3 RELAY Trial Met Primary Endpoint in First-Line Treatment of Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
PR-M03-19-NI-039
Drug Pricing
Lilly to Introduce Lower-Priced Insulin
PR-M03-19-NI-028
FDA
Lilly Receives FDA Priority Review Designation for Emgality® (galcanezumab-gnlm) Injection for the Preventive Treatment of Episodic Cluster Headache in Adults
PR-M03-19-NI-017
M&A
Lilly Completes Acquisition of Loxo Oncology
PR-M02-19-NI-041
Annoucement
Lilly and Loxo Oncology Announce Expiration of HSR Act Waiting Period in Connection with Proposed Transaction
PR-M02-19-NI-003
Oncology
Lilly to Spend $8 Billion on Loxo Oncology
PAO-M01-19-NI-016
Oncology
Lilly Reports Results of Phase 3 Soft Tissue Sarcoma Study of LARTRUVO®
PR-M01-19-NI-067
Study Results
Lilly Announces Publication of Analyses Showing Benefit of the Addition of Verzenio®(abemaciclib) in Multiple Subgroups of Patients with Advanced Breast Cancer
PR-M12-18-NI-085
Investment
NextCure Bags $40 Million from Eli Lilly
PAO-M11-18-NI-010
Real World Data
Initial results from EMPRISE real-world evidence study show Jardiance® was associated with reduced risk for hospitalization for heart failure compared with DPP-4 inhibitors
PR-M11-18-NI-032
RNAi
Eli Lilly, Dicerna to Collaborate on RNAi Drug Development
PAO-M11-18-NI-006
Rheumatology
New Data Showcasing Lilly's Growing Commitment in Rheumatology to be Featured at the ACR/ARHP Annual Meeting
PR-M10-18-NI-062
Clinical Trials
New Diabetes Drug Shows Promise in Phase 2 Study
PAO-M10-18-NI-012
Positive Opinion
Lilly Receives Positive CHMP Opinion for Emgality™ (galcanezumab) for the Prophylaxis of Migraine in Adult
PR-M09-18-NI-092
Appointment
New Lilly Oncology President Selected
PAO-M09-18-NI-002
Research Collaboration
Lilly Announces Extension of Cancer Research Collaboration with Dana-Farber Cancer Institute
PR-M08-18-NI-003
Phase 3
Lilly to Present Phase 3 Data at AHS 2018 Highlighting Innovative Potential Treatments for Migraine and Cluster Headache
PR-M06-18-NI-085
«
2
3
»
.svg)
